Maternal Blood Test Now Maps Fetal Genome Without Invasive Risk

Researchers at the European Society for Human Genetics Conference (June 13–16, 2026) have made whole-fetal-genome sequencing feasible from a single maternal blood draw. The advance sidesteps amniocentesis, which carries a 0.1–0.5% miscarriage risk. Plummeting costs and faster sequencing have moved what was theoretical in 2012 into clinical reality. Adoption now hinges on regulatory clearance and whether health systems will fund testing widely.